Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole.
Chagas' Disease, caused by the protozoan parasite Trypanosoma cruzi, is responsible for up to 41% of the heart failures in endemic areas in South America and is an emerging infection in regions of North America, Europe, and Asia. Treatment is suboptimal due to two factors. First, the lack of an...
Saved in:
Main Authors: | Claudia Magalhães Calvet (Author), Tatiana Araújo Silva (Author), Diane Thomas (Author), Brian Suzuki (Author), Ken Hirata (Author), Jair Lage Siqueira-Neto (Author), James H McKerrow (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.
by: Chiung-Kuang Chen, et al.
Published: (2010) -
Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments.
by: Lívia de Figueiredo Diniz, et al.
Published: (2013) -
Anti-Trypanosoma cruzi antibody profiling in patients with Chagas disease treated with benznidazole assessed by genome phage display.
by: Luis Antonio Rodriguez Carnero, et al.
Published: (2023) -
Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics.
by: Andrea Trochine, et al.
Published: (2014) -
Chagas cardiomyopathy manifestations and Trypanosoma cruzi genotypes circulating in chronic Chagasic patients.
by: Juan David Ramírez, et al.
Published: (2010)